These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 2577313)

  • 1. Effects of cardiovascular disease on pharmacokinetics.
    Rodighiero V
    Cardiovasc Drugs Ther; 1989 Oct; 3(5):711-30. PubMed ID: 2577313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antihypertensive agents: clinical pharmacology and therapeutic monitoring.
    White WB; Pandit RS
    Clin Lab Med; 1987 Sep; 7(3):607-23. PubMed ID: 2888562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular drug therapy in the elderly: theoretical and practical considerations.
    Williams BR; Kim J
    Drugs Aging; 2003; 20(6):445-63. PubMed ID: 12710864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.
    Piepho RW; Fendler KJ
    Drugs Aging; 1991 May; 1(3):194-211. PubMed ID: 1686570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs.
    Ueno K; Sato H
    Hypertens Res; 2012 Mar; 35(3):245-50. PubMed ID: 22089536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers.
    Weber C; Tam YK; Schmidtke-Schrezenmeier G; Jonkmann JH; van Brummelen P
    Eur J Clin Pharmacol; 1996; 51(1):87-90. PubMed ID: 8880057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Office and ambulatory blood pressure control in hypertensive patients treated with different two-drug and three-drug combinations.
    de la Sierra A; Banegas JR; Vinyoles E; Gorostidi M; Segura J; de la Cruz JJ; Ruilope LM
    Clin Exp Hypertens; 2016; 38(4):409-14. PubMed ID: 27159660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular drug therapy in the elderly.
    Aronow WS; Frishman WH; Cheng-Lai A
    Cardiol Rev; 2007; 15(4):195-215. PubMed ID: 17575484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcium antagonists: an antihypertensive alternative].
    Bruun NE; Pedersen OL
    Ugeskr Laeger; 1990 Feb; 152(7):453-6. PubMed ID: 2408216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacies of antihypertensive drugs.
    Aursnes I; Tvete IF; Gåsemyr J; Natvig B
    Scand Cardiovasc J; 2003 May; 37(2):72-9. PubMed ID: 12775305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug level monitoring: cardiovascular drugs.
    Ahnoff M; Ervik M; Lagerström PO; Persson BA; Vessman J
    J Chromatogr; 1985 May; 340():73-138. PubMed ID: 2862159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic Cation Transporter-Mediated Clearance of Cardiovascular Drugs: A Pharmacological Perspective.
    Hassan OT; Hassan RT; Arora RR
    Am J Ther; 2016; 23(3):e855-61. PubMed ID: 25259955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Special considerations for antihypertensive agents in dialysis patients.
    Redon J; Martinez F; Cheung AK
    Blood Purif; 2010; 29(2):93-8. PubMed ID: 20093810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
    JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.
    Yarows SA
    JAMA; 2003 Apr 23-30; 289(16):2068-9; author reply 2069-70. PubMed ID: 12709458
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
    Antza C; Stabouli S; Kotsis V
    Vasc Health Risk Manag; 2016; 12():443-451. PubMed ID: 27895487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.
    Messerli FH; Weber MA
    JAMA; 2003 Apr 23-30; 289(16):2067-8; author reply 2069-70. PubMed ID: 12709457
    [No Abstract]   [Full Text] [Related]  

  • 20. [Progress in the field of drug development. 18].
    Délenk-Heydenreich K; Henkler G; Keller U; Klotzbach M; Koch H; Müller W; Richter J
    Pharmazie; 1985 Nov; 40(11):745-57. PubMed ID: 2419928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.